Insider · CIK 0002034679
David Raben
officer
Files at PLRX (PLIANT THERAPEUTICS, INC.), BCAX (Bicara Therapeutics Inc.). First filing Oct 10, 2025, latest Mar 26, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $1.0M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BCAX: Bicara Therapeutics Inc.
BCAXOct 9, 2026 · close 17.50
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | Bicara Therapeutics Inc. | $104k 5,500 shares | -9% | +114% from low-7% from high | |
| 19Weak | Bicara Therapeutics Inc. | $306k 16,500 shares | -30% | +106% from low-6% from high | |
| 17Weak | Bicara Therapeutics Inc. | $205k 11,000 shares | -27% | +117% from low-11% from high | |
| 21Weak | Bicara Therapeutics Inc. | $406k 22,000 shares | -38% | +110% from low-28% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +575,000 | $0.00 | $0 | 575,000 | 10 d ago |
| Mar 25, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +5,500 | $3.79 | $21k | 60,786 | Mar 26, 2026 |
| Mar 25, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -5,500 | $18.95 | $104k | 55,286 | Mar 26, 2026 |
| Mar 25, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,500 | $0.00 | $0 | 47,413 | Mar 26, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +200 | $3.79 | $758 | 55,486 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -200 | $18.45 | $3,690 | 55,286 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +16,300 | $3.79 | $62k | 71,586 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -16,300 | $18.52 | $302k | 55,286 | Mar 5, 2026 |
| Mar 3, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -200 | $0.00 | $0 | 69,213 | Mar 5, 2026 |
| Mar 4, 2026 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -16,300 | $0.00 | $0 | 52,913 | Mar 5, 2026 |
| Feb 2, 2026 | BCAX Bicara Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 4, 2026 |
| Dec 26, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock | +19,789 | $3.79 | $75k | 55,286 | Dec 29, 2025 |
| Dec 26, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative | -19,789 | $0.00 | $0 | 98,987 | Dec 29, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +5,500 | $3.79 | $21k | 40,997 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -5,500 | $18.45 | $101k | 35,497 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +4,594 | $3.79 | $17k | 40,091 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -4,594 | $18.84 | $87k | 35,497 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +906 | $3.79 | $3,434 | 36,403 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -906 | $18.84 | $17k | 35,497 | Nov 25, 2025 |
| Nov 24, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,500 | $0.00 | $0 | 123,370 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,594 | $0.00 | $0 | 118,776 | Nov 25, 2025 |
| Nov 25, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -906 | $0.00 | $0 | 69,413 | Nov 25, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Common Stock10b5-1 | +22,000 | $3.79 | $83k | 57,497 | Oct 10, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | SOpen-market sale Common Stock10b5-1 | -22,000 | $18.45 | $406k | 35,497 | Oct 10, 2025 |
| Oct 9, 2025 | BCAX Bicara Therapeutics Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,000 | $0.00 | $0 | 128,870 | Oct 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.